Form 8-K - Current report:
SEC Accession No. 0001628280-23-006782
Filing Date
2023-03-07
Accepted
2023-03-07 17:21:35
Documents
14
Period of Report
2023-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230307.htm   iXBRL 8-K 36038
2 EX-99.1 a2022q4ex991earningsrelease.htm EX-99.1 303908
6 cumberlandpharmalogoa01.jpg GRAPHIC 37721
  Complete submission text file 0001628280-23-006782.txt   555746

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230307.xsd EX-101.SCH 2011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230307_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230307_pre.xml EX-101.PRE 12609
8 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230307_htm.xml XML 10578
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 23713842
SIC: 2834 Pharmaceutical Preparations